Cell-free circulating tumor DNA in plasma of non-small cell lung cancer patients: The role in EGFR T790 M mutation testing

被引：0
|
作者：
Sekerus, V. [1 ,2 ]
Stojanovic, G. [1 ]
Bursac, D. [1 ,2 ]
Tegeltija, D. [1 ,2 ]
Stolic, M. [3 ]
Andrijevic, I. [1 ,2 ]
机构：
[1] Inst Pulm Dis Vojvodina, Sremska Kamen, Serbia
[2] Univ Novi Sad, Fac Med, Novi Sad, Serbia
[3] Special Hosp Lung Dis Dr Jovan Bulajic, Brezovik, Montenegro
来源：
CLINICA CHIMICA ACTA | 2019年 / 493卷
关键词：
D O I：
10.1016/j.cca.2019.03.1205
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
W286
引用
收藏
页码：S574 / S574
页数：1
相关论文
共 50 条
  • [41] The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
    Cheng, Wen-Chien
    Hsia, Te-Chun
    Tu, Chih-Yen
    Chen, Hung-Jen
    ONCOTARGETS AND THERAPY, 2020, 13 : 13425 - 13435
  • [42] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [43] Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
    Li, Hang
    Hu, Haichuan
    Wang, Rui
    Pan, Yunjian
    Wang, Lei
    Li, Yuan
    Zhang, Yang
    Ye, Ting
    Zhang, Yiliang
    Li, Bin
    Shen, Lei
    Sun, Yihua
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2014, 7 : 513 - 524
  • [44] Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation
    Wang, Shuyuan
    Yan, Bo
    Zhang, Yanwei
    Xu, Jianlin
    Qiao, Rong
    Dong, Yu
    Zhang, Bo
    Zhao, Yiming
    Zhang, Lele
    Qian, Jie
    Lu, Jun
    Zhao, Ruiying
    Han, Baohui
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2880 - 2886
  • [45] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [46] Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
    Ai, Bo
    Liu, Huiquan
    Huang, Yu
    Peng, Ping
    ONCOTARGET, 2016, 7 (28) : 44583 - 44595
  • [47] Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition
    Oellerich, Michael
    Christenson, Robert H.
    Beck, Julia
    Walson, Philip D.
    CLINICA CHIMICA ACTA, 2019, 495 : 481 - 486
  • [48] Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
    Jenkins, S.
    Yang, J.
    Ramalingam, S.
    Yu, K.
    Patel, S.
    Weston, S.
    Lawrance, R.
    Cantarini, M.
    Janne, P.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S153 - S154
  • [49] Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naive Stage IV Non-Small Cell Lung Cancer Patients
    Kim, Bo-Guen
    Jang, Ja-Hyun
    Kim, Jong-Won
    Shin, Sun Hye
    Jeong, Byeong-Ho
    Lee, Kyungjong
    Kim, Hojoong
    Kwon, O. Jung
    Ahn, Myung-Ju
    Um, Sang-Won
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [50] Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients
    Fajiu Li
    Jie Huang
    Dongyuan Ji
    Qinghua Meng
    Chuanhai Wang
    Shi Chen
    Xiaojiang Wang
    Zhiyang Zhu
    Cheng Jiang
    Yi Shi
    Shuang Liu
    Chenghong Li
    Clinical and Translational Oncology, 2017, 19 : 1283 - 1291
12345